CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02876510
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:53.975255+00:00
Published At: 2025-02-04T00:00:00+00:00
Record Updated At: 2025-02-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cancer", "Solid Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-02-04"
protocolSection.identificationModule.nctId: "NCT02876510"
protocolSection.identificationModule.officialTitle: "Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog\u00ae IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.